Key points are not available for this paper at this time.
using supernatant depletion assay, with peptide 13 showing a trend toward higher affinity. Additionally, the inhibitory effect of peptides on homodimerization of the BACH2 BTB domain was investigated through coimmunoprecipitation studies, revealing peptide 13 as a potential disruptor of homodimerization. Based on these observations, peptide 13 has been identified as a putative BACH2 negative regulator. Furthermore, limitations and future directions are also discussed.
Acar et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: